Abstract | BACKGROUND: FINDINGS:
Paraffin tumor blocks of 75 patients with representative STS subtypes were evaluated. The methylation status of the MGMT promoter was assessed by methylation-specific polymerase-chain-reaction analysis (PCR). Furthermore, immunohistochemistry was applied to verify expression of MGMT. MGMT gene silencing was assumed if MGMT promoter methylation was present and the fraction of tumor cells expressing MGMT was 20% or less. Methylation specific PCR detected methylated MGMT promoter in 10/75 cases. Immunohistochemical staining of nuclear MGMT was negative in 15/75 cases. 6/75 tumor samples showed MGMT promoter methylation and negative immunohistochemical nuclear staining of MGMT. In none of the tested STS subtypes we found a fraction of tumors with MGMT silencing exceeding 22%. CONCLUSION:
|
Authors | Jens Jakob, Maren Hille, Christian Sauer, Philipp Ströbel, Frederik Wenz, Peter Hohenberger |
Journal | Radiation oncology (London, England)
(Radiat Oncol)
Vol. 7
Pg. 180
(Oct 30 2012)
ISSN: 1748-717X [Electronic] England |
PMID | 23110891
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- DNA, Neoplasm
- Tumor Suppressor Proteins
- DNA Modification Methylases
- MGMT protein, human
- DNA Repair Enzymes
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(genetics)
- DNA Methylation
- DNA Modification Methylases
(genetics, metabolism)
- DNA Repair Enzymes
(genetics, metabolism)
- DNA, Neoplasm
(genetics)
- Female
- Gene Silencing
- Humans
- Immunoenzyme Techniques
- Male
- Middle Aged
- Promoter Regions, Genetic
(genetics)
- Real-Time Polymerase Chain Reaction
- Sarcoma
(genetics)
- Tumor Suppressor Proteins
(genetics, metabolism)
- Young Adult
|